CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Learn about the best miles cards with no fees to enjoy travel rewards without incurring additional costs!
11,301 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
OpenAI has filed confidential IPO paperwork with the SEC, signaling a public listing could be on the horizon. The mov...
Two very different apparel plays: FIGS targets a niche medical market with growth potential, while Gildan Activewear ...
What the ehang 2026 earnings call signals for growth, profitability, and risk. This guide breaks down management mess...
A 68-year-old retiree faced a surprise tax bill after selling $30,000 of stock. The move pushed provisional income ov...
SpaceX's IPO could be a watershed moment for growth investors, but it carries meaningful risks. This guide breaks dow...
A new Ethereum standard dubbed pERC-20 would hide balances and transfers by default, using zero-knowledge proofs to c...
Adobe has fallen sharply in 2026, prompting a rotation debate toward Alphabet as AI momentum and big-cap investments ...
Bitcoin miners face mounting strain as key metrics show bitcoin miners under pressure amid softer prices, signaling s...
A sudden pullback in a high-profile space stock captured headlines. This article breaks down the factors behind intui...
A sharp drop in a space-focused stock can spark questions about risk and timing. This guide breaks down the real reas...
Starboard Value disclosed a dramatic reshuffle in its Q1 2026 13F, exiting Salesforce and Autodesk and plowing into L...